Psoriasis Clinical Trial
Official title:
The Effectiveness of a Mindful Parenting Intervention for Parents of Children With Psoriasis and Parents of Children With Eczema: A Single Group Case Series
This study investigates the impact of a mindful parenting intervention on parents of children with psoriasis or eczema. More specifically, this study will investigate the impact of the group on both the child and the parents mental health and quality of life.
Psoriasis and eczema are chronic inflammatory skin conditions that affect up to 2% and 20% of
children respectively (Mahe, 2016; Plötz, Wiesender, Todorva & Ring, 2014). These skin
conditions are associated with poorer mental health in the children themselves and in their
parents (Megna et al., 2015; Hammer-Helmich et al., 2016). Little research has investigated
ways of reducing parental stress in parents of children with chronic health conditions, such
as psoriasis and eczema.
"Mindful Parenting" interventions offer one potential way of improving mental health and
quality of life in parents and their children. Mindful parenting refers to a parenting style
which involves paying close, non-judgemental attention to the child (Duncan et al., 2009).
However, no research has investigated the impact of mindful parenting interventions on
children with skin conditions and their parents.
The main aim of the current study is to investigate whether a mindful parenting intervention
can improve mental health and quality of life in children with psoriasis/eczema and their
parents. A single-group case-series design will be adopted, whereby participants will act as
their own control; data collected from participants during and after they have received the
intervention will be compared to data collected before they have received the intervention.
Interviews will also be conducted after the intervention, to explore participants experience
of the group.
The investigators predict that the intervention will improve mental health and quality of
life in children with psoriasis/eczema and their parents. More specifically, we predict:
- There will be a reduction in negative parental idiosyncratic measures of stress
throughout the intervention phase, in comparison to baseline phase, that will be
maintained in the follow-up phase.
- There will be an improvement in positive parental idiosyncratic measures of stress
during the intervention phase in comparison to baseline phase that will be maintained in
the follow-up phase.
- There will be a significant increase in levels of mindful parenting following the
intervention phase, in comparison to baseline phase, that will be maintained in the
follow-up phase.
- There will be a significant decrease in levels of parental stress at end of intervention
phase compared to baseline phase that will be maintained in the follow-up phase.
- There will be a significant increase in parental quality of life and paediatric quality
of life at the end of intervention phase compared to baseline phase that will be
maintained in the follow-up phase .
- There will be a significant improvement in psoriasis severity and itch at the follow-up
phase compared to the baseline phase.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |